Viracta Therapeutics appoints Michael Faerm as CFO, base salary $480K with stock options

Viracta Therapeutics, Inc.

Michael Faerm appointed CFO effective May 13, 2024; previously interim CFO at Harpoon Therapeutics.
Annual base salary $480,000, target bonus up to 40% of base salary.
Initial option to purchase 500,000 shares of common stock, vesting over 4 years.
Additional option for 340,000 shares if financing extends runway through FY2025 by Dec 31, 2024.
Board increased shares reserved under Inducement Plan by 1,200,000, total 3,575,000 shares.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Melody Burcar

Senior Vice President of Finance

Viracta Therapeutics, Inc.

Effective: 2024-05-13
Successor: Michael Faerm
Filed: May 14, 2024, 7:59 PM ET

Melody Burcar, the Company’s Senior Vice President of Finance, will no longer serve as the Company’s interim principal financial officer and interim principal accounting officer.

Appointed

Michael Faerm

Chief Financial Officer

Viracta Therapeutics, Inc.

Effective: 2024-05-13
Filed: May 14, 2024, 7:59 PM ET

On May 11, 2024, the Board of Directors ("Board") of Viracta Therapeutics, Inc. (the "Company") appointed Michael Faerm to serve as the Company’s Chief Financial Officer, effective May 13, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..

Action: no longer serve
Role: Senior Vice President of Finance

Exact text from the filing

Melody Burcar, the Company’s Senior Vice President of Finance, will no longer serve as the Company’s interim principal financial officer and interim principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Faerm was appointed as Chief Financial Officer at Viracta Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 11, 2024, the Board of Directors ("Board") of Viracta Therapeutics, Inc. (the "Company") appointed Michael Faerm to serve as the Company’s Chief Financial Officer, effective May 13, 2024

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-059668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.